ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to compare 2 types of pain control methods and determine which is more effective postoperatively for laparoscopic colorectal surgery. Group 1 will receive an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid. Group 2 will receive an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indiana University

Criteria

Inclusion Criteria:

• Patients undergoing an elective laparoscopic colorectal procedure at Indiana University Hospital or Methodist Hospital

• ASA Class 1, 2, 3 (American Society of Anesthesiologists physical status classification system)

• Age 18 to 80 years (male or female)

• BMI < 40kg/m2

• Desires regional anesthesia for postoperative pain control

Exclusion Criteria:

• Any contraindication for neuraxial analgesia or ESP block procedure

• Contraindications for neuraxial analgesia include: Elevated intracranial pressure (except in cases of pseudo-tumor cerebri), infection at the site of injection, lack of consent from the patient, patient refusal, true allergy to any drug used in the spine, and uncorrected hypovolemia.

• Contraindications for ESP block procedure include: Infection at the site of injection, patient refusal, true allergy to any of the drugs used in the block, and lack of patient consent.

• Any patient undergoing a laparoscopic abdominoperineal resection.

• Any physical, mental or medical conditions which, in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery.

• Known true allergy to the study medications (morphine, bupivacaine, decadron, Tylenol, Celebrex)

• Takes over 30 mg of oral morphine equivalents daily

• Any history of substance abuse in the past 6 months

• End stage liver disease, end stage renal disease

• Body weight of < 50 kg